In early 2021, individual investors and institutions hurled money at Moderna stock as if future growth were unlimited.

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biotechnology company focused on developing small molecule drugs for viral infections and liver diseases, is navigating a critical phase in its evolution.

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever received at the company. | While Stéphane Bancel received a ...

RSV is a highly contagious seasonal respiratory virus and a ... By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at ...

highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at the 13 th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu ...

RSV is a highly contagious seasonal respiratory ... technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of ...